Neurogene’s Value Tanks On Gene Therapy Side-Effect Details
The company is trading below cash after admitting that an adverse event in a Rett syndrome trial left a patient critically ill.
The company is trading below cash after admitting that an adverse event in a Rett syndrome trial left a patient critically ill.